Endocrinology Unit, Department of Internal Medicine (DiMI), University of Genova, Genoa, Italy.
Medical Oncology Unit, IRCCS Policlinico San Martino, Genoa, Italy.
J Endocrinol Invest. 2017 Nov;40(11):1265-1269. doi: 10.1007/s40618-017-0692-0. Epub 2017 May 26.
Octreotide and lanreotide, the first-generation somatostatin analogs, successfully control hormone hyperproduction, and related syndromes, in patients with acromegaly and neuroendocrine tumors. However, their anti-tumor effect, rather evident in large number of pituitary adenomas in acromegalic patients, has been hypothesized for a long time in patients with neuroendocrine tumors as well, although a significant tumor shrinkage has rarely been observed. However, the recent publication of the CLARINET study has strengthened the evidence, already emerged with the PROMID trial, that the long-term treatment with the first-generation long-acting somatostatin analogs may exert an anti-tumor activity on G1 and G2 enteropancreatic neuroendocrine tumors, as well. After the publication, majority of international guidelines have updated their algorithms in line with these results and this class of drugs obtained the indication as anti-tumor agents in the majority of patients with neuroendocrine tumors.
奥曲肽和兰瑞肽是第一代生长抑素类似物，可成功控制肢端肥大症和神经内分泌肿瘤患者的激素过度分泌和相关综合征。然而，它们的抗肿瘤作用在肢端肥大症患者的大量垂体腺瘤中早已得到证实，尽管很少观察到明显的肿瘤缩小。然而，最近发表的 CLARINET 研究加强了证据，这一证据已经在 PROMID 试验中出现，即第一代长效生长抑素类似物的长期治疗可能对 G1 和 G2 肠胰神经内分泌肿瘤也具有抗肿瘤活性。该研究发表后，大多数国际指南都根据这些结果更新了其算法，此类药物在大多数神经内分泌肿瘤患者中获得了抗肿瘤药物的适应证。
